Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

6,630 studies for “New York”

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruiting
NCT05987241Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Renal Pelvis Urothelial Carcinoma · Muscle Invasive Ureter Urothelial Carcinoma · Muscle Invasive Urethral Urothelial Carcinoma
United States, Canada
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Recruiting
NCT06395103Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma
United States, Australia, Belgium, Brazil, Canada +18 more
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseRecruiting
NCT07363694Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Pfizer
Moderate to Severe Chronic Obstructive Pulmonary Disease
United States, Argentina, Canada, China, India +3 more
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspended
NCT01810913Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 · Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7 · Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
United States, Canada, Hong Kong
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruiting
NCT07061977Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Locally Advanced Cervical Adenocarcinoma · Locally Advanced Cervical Adenosquamous Carcinoma · Locally Advanced Cervical Squamous Cell Carcinoma · Stage IIIA Cervical Cancer FIGO 2018
United States
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRecruiting
NCT05552157Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Washington University School of Medicine
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
United States, Argentina, Australia, Canada, Colombia +10 more
VE303 for Prevention of Recurrent Clostridioides Difficile InfectionRecruiting
NCT06237452Phase 3Updated Jul 27, 2026
Sponsor: Vedanta Biosciences, Inc.
Clostridium Difficile · Clostridium Difficile Infections · Clostridium Difficile Infection Recurrence · Clostridioides Difficile Infection
United States, Australia, Belgium, Brazil, Bulgaria +19 more
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruiting
NCT05112601Phase 2Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma
United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive Not Recruiting
NCT05753501Phase 1Updated Jul 27, 2026
Sponsor: AbbVie
Hematologic Cancer
United States, Canada, France, Germany, Israel +4 more
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruiting
NCT06589804Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma · Metastatic Laryngeal Squamous Cell Carcinoma · Metastatic Oral Cavity Squamous Cell Carcinoma
United States
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanRecruiting
NCT07196644Phase 2Updated Jul 27, 2026
Sponsor: AbbVie
Solid Tumors Harboring MET Amplification
United States, Israel, Japan, South Korea, Spain
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)Active Not Recruiting
NCT07400653Phase 3Updated Jul 27, 2026
Sponsor: Pfizer
Obesity · Overweight and/or Obesity · Overweight · Diabetes, Type 2
United States, Argentina, Bulgaria, Canada, Czechia +6 more
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)Active Not Recruiting
NCT04816604Phase 2Updated Jul 27, 2026
Sponsor: Gossamer Bio USA, Inc.
Pulmonary Arterial Hypertension
United States, Australia, Czechia, France, Germany +2 more
A Study of IDP-001 in Advanced or Metastatic Solid TumorsNot Yet Recruiting
NCT07602842Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: InduPro, Inc.
Advanced Solid Tumor · Metastatic Solid Tumor · Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma
United States
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)Recruiting
NCT05099003Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Malignant Glioma
United States, Australia, Canada, New Zealand
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Recruiting
NCT04267848Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma · Lung Non-Small Cell Squamous Carcinoma · Lung Non-Squamous Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8
United States, Guam
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialRecruiting
NCT07061964Phase 2Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma · Stage II Bladder Cancer AJCC v8 · Stage IIIA Bladder Cancer AJCC v8
United States
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaRecruiting
NCT05256225Phase 3Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma
United States, Puerto Rico, South Korea
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruiting
NCT03866382Phase 2Updated Jul 27, 2026
Sponsor: National Cancer Institute (NCI)
Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma · Bladder Neuroendocrine Carcinoma
United States, Puerto Rico
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell DiseaseRecruiting
NCT02675959Phase 2Updated Jul 27, 2026
Sponsor: New York Medical College
Sickle Cell Disease
United States
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic ValvesRecruiting
NCT05172973NAUpdated Jul 27, 2026
Sponsor: Edwards Lifesciences
Aortic Valve Insufficiency · Aortic Valve Stenosis
United States, Canada
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRecruiting
NCT06647498Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Washington University School of Medicine
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
United States, Argentina, Australia, Canada, Colombia +10 more
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruiting
NCT06772623Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: AbbVie
Non Small Cell Lung Carcinoma
United States, Belgium, China, France, Germany +9 more
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseRecruiting
NCT07064473Phase 3Updated Jul 27, 2026
Sponsor: Boehringer Ingelheim
Diabetes Mellitus, Type 2 · Hypertension · Cardiovascular Diseases
United States, Argentina, Australia, Austria, Belgium +46 more
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +29 more

6,630 studies found